 |
|
|
| |
Tropism Change from Screening to Baseline Matters:
Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive Patients
|
| |
| |
Reported by Jules Levin
CROI 2008, Boston
Jayvant Heera1, Mike Saag2, Prudence Ive3, Jeannette Whitcomb4, Marilyn Lewis5, Lynn McFadyen5, James Goodrich1, Howard Mayer1, Elna van der Ryst5, and Mike Westby5
1Pfizer Global Research and Development, New London, CT, USA
2University of Alabama at Birmingham, Birmingham, AL, USA
3University of the Witwatersrand, Johannesburg, South Africa
4Monogram Biosciences Inc., South San Francisco, CA, USA
5Pfizer Global Research and Development, Sandwich, UK
|
| |
|
|
|
|
|
